BDX

ResMed RMD is scheduled to release its first-quarter fiscal 2027 results on Oct. 29, after the closing bell. The renowned sleep health device maker posted adjusted earnings per share (EPS) of $2.95 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.72%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 2.78%. For the first quarter of fiscal 2027, the Zacks Consensus Estimate for ResMed's revenues is pegged at $1.39 billion, indicating an increase of 4% from the year-ago reported figure. The Zacks Consensus Estimate for fiscal first-quarter EPS suggests a 4.7% rise to $2.67. The estimate has dropped 0.7% in the past 30 days. Here's a brief review of the company's performance leading up to this announcement. Within this segment, ResMed's device revenues may have benefited from continued solid demand for sleep devices across the Americas and Rest of World. However, life support devices, including ventilators such as Astral, are likely to have seen lower unit sales. The ongoing expansion of the AirSense 11 platform into global sleep health markets is expected to have supported revenues in the first quarter of fiscal 2027. Growth is likely to have remained strong in the United States and Europe, while penetration in China may have continued to build following its recent launch. During the fourth quarter of fiscal 2026, ResMed reached an important milestone with the U.S. introduction of the AirCurve 11 ST and AirCurve 11 ST-A platforms. The company also launched the AirCurve 11 platform in Hong Kong, Singapore, Australia and New Zealand. Masks and other is also expected to have contributed. ResMed is likely to have continued the global rollout of its fabric technology masks, including AirTouch N30i and AirTouch F30i, in the first quarter of fiscal 2027. The AirFit F40, its smallest tube-down full-face mask, may also have generated strong demand. These developments are expected to have supported the segment's top line in the quarter. ResMed Inc. price-eps-surprise | ResMed Inc. Quote ResMed may have continued integrating Noctrix Health, LLC, which it acquired in June 2026. Noctrix's flagship product, Nidra, addresses restless legs syndrome (RLS), a prevalent sleep disorder worldwide after sleep apnea and insomnia. The acquisition expands ResMed's clinical sleep health portfolio into an adjacent area of unmet need. Greater clinician awareness is also likely to act as a tailwind for ResMed's results in the fiscal first quarter. The company's continuing medical education (CME) programs cover sleep physician society-approved guidelines and the benefits of continuous positive airway pressure (CPAP), automatic positive airway pressure (APAP) and bilevel positive airway pressure (PAP) therapy as frontline treatments for sleep apnea. More than 55,000 clinicians have completed its sleep apnea courses, with total course completions exceeding 95,000. ResMed has already observed increases in home sleep apnea test referrals and prescriptions for PAP therapy following training. The Zacks Consensus Estimate implies Sleep and Breathing Health revenues will increase 6.4% in the fiscal first quarter. Over the last few quarters, ResMed has continued to reshape its Residential Care Software portfolio, directing higher investments in high-growth, higher-margin businesses while reducing exposure to lower-growth, lower-margin areas, including services businesses. The strategy is aimed at returning the business to sustainable high-single-digit revenue growth and achieving double-digit operating profit growth in fiscal 2027. In line with these efforts, ResMed completed the sale of its MatrixCare business to the private equity firm Frazier Healthcare Partners on Sept. 1, marking the culmination of its portfolio management initiatives. MatrixCare represented approximately $220 million of revenues and approximately $28 million of operating profit in fiscal 2026. The divestiture is expected to have reduced the company's revenues in the fiscal first quarter. Following the transaction, the Residential Care Software portfolio comprises Brightree and MEDIFOX DAN offerings, which are likely to have made a solid contribution to revenues in the to-be-reported quarter. The Zacks Consensus Estimate projects Residential Care Software revenues to decrease 12.7% in the first quarter of fiscal 2027. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below. Earnings ESP: ResMed has an Earnings ESP of -0.60%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: Phibro Animal Health PAHC has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company's first-quarter EPS indicates an increase of 8.2% from the year-ago quarter's figure. Becton, Dickinson and Company BDX, or BD, has an Earnings ESP of +0.21% and a Zacks Rank #1. The company will release its fourth-quarter fiscal 2026 results on Nov. 5. BD's earnings outpaced estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company's fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter's figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2. IDXX's earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company's third-quarter EPS implies a jump of 9.1% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Becton Dickinson (BDX) heads into its fourth quarter fiscal 2026 report with investors focused on recent execution improvements, progress in higher growth businesses, fresh product launches, and a major U.S. manufacturing agreement. Becton Dickinson's recent news arrives after a strong run in the market, with the share price up 28.18% over the past 90 days and a 1-year total shareholder return of 40.14%. This points to building momentum as investors reassess its execution, pipeline progress, and manufacturing capacity. Scan how Becton Dickinson's recent momentum compares to other health care names by reviewing our curated list of 30 resilient stocks with low risk scores. Becton Dickinson now looks like a sharper operator with a stronger product mix, yet the share price has already sprinted ahead. Is this still a solid medical supplies leader at a reasonable tag, or has enthusiasm run too far? Becton Dickinson closed at $200.42 against a widely followed fair value estimate of $195.67, which implies a small premium that depends on execution in higher margin platforms and capital returns remaining intact. The main factor that has to go right is continued execution of the BD Excellence program, with sustained plant productivity, margin expansion, and cash flow discipline, while managing product quality and regulatory issues such as the recent infection prevention recall and warning letter. See why 28 investors see Becton Dickinson as 2% overvalued. Result: Fair Value of $195.67 (OVERVALUED) Still, the narrative can break if China weakness persists or if further product quality and regulatory issues force Becton Dickinson into heavier recalls and remediation. Find out about the key risks to this Becton Dickinson narrative. The earlier discussion leans on a fair value of $195.67, yet our DCF model points to a future cash flow value near $234.27, with Becton Dickinson trading around $200.42. That suggests investors weighing price today against modeled cash generation get a very different signal. Which story feels more convincing to you? To see how this cash flow view is built and stress test the moving parts, take a closer look at the SWS DCF model for Becton Dickinson, starting with Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Becton Dickinson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. The Becton Dickinson story so far presents mixed messages. Act promptly, review the figures independently, and consider both perspectives by examining the 4 key rewards and 2 important warning signs Do not stop with Becton Dickinson. Broaden your watchlist with fresh opportunities that match your risk comfort, income goals, and appetite for underappreciated stories. - Target resilient balance sheets and dependable fundamentals by scanning a curated list of solid balance sheet and fundamentals (26 results). - Spot potential mispriced opportunities early by reviewing a focused set of 29 high quality undervalued stocks. - Boost your income playbook by zeroing in on 6 dividend fortresses that put cash returns at the forefront. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BDX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Illumina, Inc. ILMN is set to release third-quarter 2026 results on Oct. 29, after the closing bell. The company posted adjusted earnings per share (EPS) of $1.31 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 6.5%. Illumina beat earnings in each of the trailing four quarters, the average surprise being 9.67%. The Zacks Consensus Estimate for the company's third-quarter revenues is pegged at $1.14 billion, which suggests 5% growth from the year-ago reported figure. The Zacks Consensus Estimate for earnings is pinned at $1.38 per share, which implies a 3% rise from the year-ago actuals. The estimate has remained constant in the past 60 days. Here's a brief overview of the company's performance leading up to this announcement. Illumina currently has one reportable segment, Core Illumina, following the separation of GRAIL into an independent, publicly traded company in June 2024. The company is likely to have extended its solid first-half 2026 momentum into the third quarter, driven by growing demand for its technologies. In the second quarter, Rest-of-World organic revenues exceeded the high end of management's previous guidance. Demand for the NovaSeq X platform also remained strong, with more than 95 systems placed during the quarter, more than three years after its launch. These drivers, along with disciplined expense management, may have helped Illumina deliver stronger profitability and bottom-line performance in the third quarter. Illumina, Inc. price-eps-surprise | Illumina, Inc. Quote Continued demand from clinical markets may have remained a key growth driver. Clinical growth across Rest-of-World markets may have benefited from broad-based strength across regions and applications, particularly in the United States and Canada. Strong instrument placements in recent quarters are expanding customers' sequencing capacity, which may have driven consumables growth in the to-be-reported quarter. However, research and academic markets may have remained under pressure as customers continued to exercise caution amid funding uncertainty. Although some improvement was seen in the second quarter, management noted that it was too early to call a recovery. The transition to NovaSeq X may have progressed further in the third quarter. By the end of the second quarter, approximately 83% of sequencing volumes and 59% of revenues had transitioned to the platform. Despite the ongoing shift, Illumina's sequencing consumables business may have continued to perform well. Strong demand for NovaSeq X and MiSeq i100 is also expected to have supported Sequencing instruments revenues. Within Sequencing service and other, the company is likely to have continued to gain traction in its Billion Cell Atlas program, resulting in higher data revenues from biopharma customers. In July, the Billion Cell Atlas alliance added three new member companies, including AI-native drug developer Formation Bio. Illumina's recent innovations may have supported revenue growth in the third quarter. The company launched a whole-genome MRD research workflow, a tool that runs on NovaSeq systems, designed to help customers shorten assay development timelines and lower development costs. Illumina broadened its capabilities in spatial biology with the StrataMap Spatial sequencing-based workflow. It is also seeing sustained proteomics momentum following the close of the SomaLogic acquisition. Illumina's SomaScan and SomaSeq offerings are generating strong interest and helping customers connect proteomics and genomic insights. Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below: Earnings ESP: Illumina has an Earnings ESP of +9.16%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time: Phibro Animal Health PAHC has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company's first-quarter EPS indicates an increase of 8.2% from the year-ago quarter's figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2. IDXX's earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company's third-quarter EPS implies a jump of 9.1% from the year-ago quarter's figure. Becton, Dickinson and Company BDX, or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5. BD's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company's fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Ecolab ECL is scheduled to release third-quarter 2026 results on Oct. 27, before the opening bell. In the last reported quarter, the company delivered earnings that surpassed the estimates by 0.48%. ECL's earnings beat estimates in three of the trailing four quarters and met once, delivering an average surprise of 0.49%. Currently, the Zacks Consensus Estimate for revenues is pegged at $4.67 billion, indicating growth of 12.2% year over year. The consensus mark for earnings is pinned at $2.18 per share, indicating an improvement of 5.3%. Ecolab is expected to have sustained its growth momentum in the third quarter of 2026, supported by stronger pricing, resilient demand across core businesses and continued strength in its high-growth platforms. Global High-Tech, Life Sciences, Ecolab Digital and Pest Elimination are likely to have remained key growth drivers, benefiting from AI infrastructure investments, market share gains in bioprocessing, rising adoption of connected solutions and continued customer demand for productivity-enhancing technologies. However, elevated commodity costs, ongoing geopolitical disruptions and continued investments in growth businesses are likely to have influenced the company's margin and earnings performance. Within the Global Industrial segment, Global High-Tech is expected to have remained a key contributor to growth, supported by strong demand for semiconductor manufacturing solutions and data center cooling technologies. In the second quarter, the business delivered 29% growth, reflecting the rapid expansion of AI infrastructure. The acquisition of CoolIT Systems, which closed in July, is expected to have further strengthened Ecolab's exposure to direct-to-chip liquid cooling and expanded its ability to provide integrated water, energy and cooling solutions. Life Sciences is also likely to have remained a strong performer, following 15% growth in the second quarter, driven by market share gains in bioprocessing, pharmaceuticals and personal care, as well as improved purification performance. Investments in manufacturing capacity and innovation are expected to support further growth, although continued spending to expand the business could influence reported margins. Meanwhile, Food & Beverage is likely to have benefited from the One Ecolab strategy and cross-selling opportunities, while Paper and Heavy Water could have continued their gradual recovery following signs of stabilization in the preceding quarter. The Global Institutional & Specialty segment is expected to have maintained steady growth, supported by market share gains, value pricing and demand from restaurant, hotel, quick-service restaurant and specialty customers. In the second quarter, the segment delivered 4% organic growth despite softer U.S. restaurant traffic, highlighting the resilience of Ecolab's customer relationships and its ability to outperform underlying markets. Continued cross-selling under the One Ecolab initiative and demand for solutions that improve productivity while reducing water and energy consumption are likely to have supported performance. Pest Elimination is also expected to have benefited from the expansion of its Pest Intelligence platform and connected-device offerings, while Ecolab Digital is likely to have continued to capitalize on growing adoption of software and subscription-based solutions. Pricing realization and commodity inflation are expected to remain key factors influencing Ecolab's third-quarter performance. In the second quarter, pricing strengthened to 4%, and management expected pricing to reach 5% to 6% in the second half of 2026 as energy surcharges were fully realized. The company also anticipated high-single-digit commodity cost inflation for the remainder of the year. Although pricing actions are expected to help offset higher input costs, the timing of recovery and the impact of acquisition-related expenses could influence reported earnings and margins. Management's second-half outlook called for organic sales growth of 6% to 7% and an adjusted operating income margin of 19%, while the full-year 2026 adjusted EPS outlook was raised to $8.05-$8.25, representing growth of 7% to 10% year over year. Investors will look for evidence that pricing is keeping pace with inflation, volumes remain resilient and productivity initiatives continue to support profitability. Investors will also monitor the contribution from CoolIT and the pace of integration across Ecolab's Global High-Tech platform. Management expects the combined Global High-Tech business, including Ovivo and CoolIT, to grow more than 25% annually and reach $4 billion in sales by 2030, with an operating income margin of 25%. However, management indicated that it was too early to revise CoolIT's near-term growth expectations following the acquisition, despite its strong pre-acquisition sales momentum. Commentary on demand across AI infrastructure, Life Sciences growth, the recovery in traditional industrial businesses and the trajectory of pricing and margins will be important as Ecolab works toward its long-term targets of 5% to 7% organic sales growth, a 20% operating income margin in 2027 and adjusted EPS growth of 12% to 15% beyond 2026. Ecolab Inc. price-eps-surprise | Ecolab Inc. Quote Our proven model does not predict an earnings beat for ECL this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.22%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company has a Zacks Rank #4 (Sell) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: Phibro Animal Health PAHC has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company's first-quarter EPS indicates an increase of 8.2% from the year-ago quarter's figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2. IDXX's earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company's third-quarter EPS implies an increase of 9.1% from the year-ago quarter's figure. Becton, Dickinson and Company BDX or BD has an Earnings ESP of +3.28% and a Zacks Rank #2. The company is due to release fourth-quarter fiscal 2026 results on Nov. 5. BD's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company's fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Danaher Corporation DHR reported third-quarter 2026 adjusted earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.92 by 9.9%. The bottom line increased 11.6% year over year from $1.89 per share. Stronger profitability in the Biotechnology segment supported results. Revenues of $6.55 billion were in line with the consensus estimate of $6.55 billion and grew 8.5% year over year. Core sales rose 3.0%, while core sales excluding respiratory testing advanced 5.5%. Acquisitions contributed to reported growth, led by the Diagnostics segment. Revenues from the Biotechnology segment totaled $1.81 billion, up 0.5% year over year from $1.80 billion. Core sales rose 5.0%. Adjusted operating profit increased to $756 million from $669 million, while adjusted operating margin expanded 460 basis points to 41.8%. The segment's reported operating profit rose to $477 million from $352 million. Life Sciences revenues were $1.87 billion, up 4.0% from $1.79 billion in the prior-year quarter. Core sales increased 4.5%. Adjusted operating profit climbed to $404 million from $376 million, and adjusted operating margin improved 70 basis points to 21.7%. Reported operating profit increased to $259 million from $222 million. Diagnostics sales totaled $2.88 billion, increasing 17.0% from $2.46 billion a year earlier. Acquisitions contributed 16.5 percentage points to reported growth. Core sales edged up 0.5%, but core sales excluding respiratory testing increased 7.0%. Adjusted operating profit increased to $831 million from $728 million, although adjusted margin narrowed 80 basis points to 28.8%. The acquisition-led expansion in the Diagnostics segment contrasted with the relatively modest growth in underlying respiratory-related testing. Respiratory testing revenues were approximately $350 million compared with about $500 million in the year-ago period. The decline remained a headwind to overall core growth. At the company level, acquisitions and divestitures contributed 6.5% to reported sales growth. Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote Danaher's cost of sales rose 7.4% year over year to $2.72 billion. Gross profit increased 8.9% to $3.84 billion, with gross margin of 58.5% compared with 58.2% a year earlier. Selling, general and administrative expenses increased 8.4% to $2.16 billion. Research and development expenses rose 14.6% to $433 million. Operating profit increased 7.9% to $1.25 billion, while reported operating margin slipped to 19.0% from 19.1%. Adjusted operating profit rose to $1.90 billion from $1.69 billion, lifting adjusted operating margin to 29.0% from 27.9%. Exiting the third quarter, DHR had cash and equivalents of $5.68 billion compared with $4.62 billion at 2025-end. Long-term debt was $24.39 billion at the end of the quarter compared with $18.42 billion at the end of December 2025. Danaher generated net cash of $4.74 billion from operating activities in the first nine months of 2026 compared with $4.30 billion in the previous year's comparable period. Capital expenditures totaled $761 million in the same period, down 3.1% year over year. Free cash flow increased 13.0% year over year to $3.98 billion in the first nine months of 2026. In the same period, DHR paid out dividends of $790 million, up 21.2% on a year-over-year basis. For the fourth quarter of 2026, Danaher projects core revenue growth, excluding respiratory testing, of 4.0-5.0% year over year. Respiratory revenues are expected to create a headwind of roughly 150 basis points, resulting in anticipated overall core sales growth of approximately 3.0%. Adjusted operating margin is projected at about 29.5%. For full-year 2026, Danaher raised its adjusted earnings guidance to $8.57-$8.62 per share from the prior range of $8.45-$8.60. The company expects full-year core revenue growth of about 2.5%, with mid-single-digit growth excluding respiratory testing. Its Life Sciences business is forecast to deliver 3.0-4.0% core sales growth for the year. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. Acadia Healthcare Company, Inc. ACHC has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4. Acadia Healthcare's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%. Agios Pharmaceuticals, Inc. AGIO has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5. Agios Pharmaceuticals' earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%. Becton, Dickinson and Company BDX has an Earnings ESP of +0.21% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 (ended September 2026) results on Nov. 5. Becton's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Boston Scientific Corporation BSX is slated to report third-quarter 2026 results on Oct. 28, before the market opens. The renowned medical device manufacturer posted earnings per share (EPS) of 86 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.61%. The company topped earnings estimates in three of the trailing four quarters and broke even once, the average surprise being 2.95%. For the third quarter of 2026, the Zacks Consensus Estimate for Boston Scientific's revenues is pegged at $5.17 billion, indicating an increase of 2.1% from the year-ago reported figure. The Zacks Consensus Estimate for the company's third-quarter EPS suggests a 1.3% rise to 76 cents. The estimate has dropped 5% in the past 30 days. Let's briefly review the company's performance leading up to this announcement. In the third quarter of 2026, the segment may have contributed due to continued strength in Endoscopy and Neuromodulation. Endoscopy sales are likely to have gained from the biliary franchise, led by the AXIOS Stent and Delivery System, and the core gastrointestinal (GI) franchise. Boston Scientific also secured FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges, allowing physicians to streamline procedural steps while performing endoscopic ultrasound biliary drainage. Initial cases had received positive feedback. Neuromodulation is likely to have benefited from the strength of its comprehensive pain portfolio, led by the Intracept Intraosseous Nerve Ablation System. The acquired Nalu Medical may have provided another quarter of solid sales contribution, with integration efforts continuing. In the brain franchise, Boston Scientific's global growth may have been favorably supported by the continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the United States. Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote Meanwhile, similar to the previous quarter, Urology may have faced continued headwinds from weakness in the stone franchise due to volume-based procurement in China and commercial disruption in sacral neuromodulation. The Zacks Consensus Estimate projects MedSurg revenues to increase 1.6% year over year in the third quarter. In the third quarter of 2026, Boston Scientific may have faced continued weakness in two historically strong Cardiovascular businesses. During the July earnings call, management lowered its full-year organic revenue and profitability outlook, citing a more challenging second half of 2026 than previously expected. WATCHMAN sales were hurt by an unexpected slowdown in the U.S. market, as compounding clinical evidence impacted referral patterns. In Electrophysiology ("EP"), the level of competitive share movement in the U.S. market was greater than anticipated. The Cardiac Rhythm Management ("CRM") business may remain a drag on the quarter's results, reflecting continued competitive pressures and gaps within the product portfolio. Weakness across its low-voltage and high-voltage businesses is likely to have persisted. On a positive note, strength across the company's broad diagnostic portfolio may have helped offset some of the pressures. Boston Scientific is also expected to have seen sustained momentum in its Interventional Cardiology business, driven by continued strength in DCB, imaging and complex PCI. Vascular Therapies results may benefit from broader adoption of Varithena and the drug-eluting portfolio. Following strong reception of the SEISMIQ IVL device for its clinical differentiation, the company is likely to have continued to ramp up its supply. Interventional Oncology and Embolization is also expected to have delivered strong global growth, aided by demand for its broad range of technologies. According to the Zacks Consensus Estimate, Cardiovascular revenues are expected to see a 0.7% decline from the prior-year period. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see. Earnings ESP: Boston Scientific has an Earnings ESP of -3.63%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: Phibro Animal Health PAHC has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company's first-quarter EPS indicates an increase of 8.2% from the year-ago quarter's figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2. IDXX's earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company's third-quarter EPS implies a jump of 9.1% from the year-ago quarter's figure. Becton, Dickinson and Company BDX, or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5. BD's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company's fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Becton, Dickinson and Company BDX, popularly known as BD, recently reported positive nine-month results from the iliac cohort of the AGILITY trial evaluating its Revello Vascular Covered Stent for treating iliac artery disease, a form of peripheral artery disease (PAD). The findings, presented at VIVA 2026, showed promising safety and effectiveness and support continued clinical evaluation of the device. The results are encouraging for BD as it seeks to strengthen its position in the peripheral vascular market through product innovation and clinical evidence. If subsequent follow-up confirms the device's durability and effectiveness, Revello could expand BD's growth opportunities in vascular intervention. Although Revello is CE-marked, it remains under clinical development in the United States and is limited to investigational use under U.S. law. Its commercial potential will depend on further clinical results and regulatory progress. Following the announcement on Oct. 7, BDX stock has gained more than 2% till yesterday's close. Year to date, shares of the company have lost 2.7% against the industry's 9.5% growth and the S&P 500's 12.5% rise. The positive AGILITY trial results could support BDX's long-term growth by strengthening its portfolio of peripheral vascular intervention products and expanding clinical evidence for the Revello Vascular Covered Stent. Favorable outcomes may improve physician confidence in the device and support its adoption if it secures the necessary regulatory approvals. This could create an additional growth opportunity for BD in treating peripheral artery disease while complementing its broader vascular portfolio. However, long-term revenue contribution will depend on the completion of clinical follow-up, regulatory clearance in the United States and the device's eventual commercial uptake. BDX currently has a market capitalization of $51.63 billion. Image Source: Zacks Investment Research BD's AGILITY Investigational Device Exemption trial evaluated the Revello Vascular Covered Stent in patients with iliac artery disease, which can restrict blood flow to the legs and feet, causing pain, cramping and reduced mobility. The iliac cohort enrolled 120 patients across 28 investigational sites in the United States, Europe, Australia and New Zealand. At nine months, the study met its primary composite safety and effectiveness endpoint, with a failure rate of just 2.8%, well below the prespecified performance goal of 19%. The results also showed 97.2% primary patency, indicating that the treated arteries remained open. Trial data also demonstrated 98.3% freedom from clinically driven target lesion revascularization, suggesting a low need for repeat procedures due to clinical symptoms. Additionally, there were no device- or procedure-related deaths, no major amputations in the target limb at or above the ankle, or unanticipated serious adverse device effects. These findings support the stent's performance in treating iliac artery disease, including cases involving moderate-to-severe lesion calcification. The Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with radial resistive force tailored to the iliac arteries. Beyond safety and vessel patency, patients treated in the AGILITY trial showed improvements in disease severity and walking ability. The mean Rutherford category, a measure of peripheral artery disease severity, improved from 3.0 at baseline to 0.3 at nine months, while the mean Walking Impairment Questionnaire score increased by 31.7 points. Women accounted for approximately 41% of enrolled patients, adding to the diversity of the study population. Clinical follow-up in the iliac cohort will continue through 36 months to assess the durability of the results. BD also completed enrollment in the trial's superficial femoral and proximal popliteal artery cohort in August 2026, extending the study's evaluation of the device across additional peripheral vascular applications. Continued positive results and progress toward regulatory approval could strengthen BD's competitive position in peripheral intervention, although broader commercial adoption will depend on longer-term clinical outcomes and regulatory developments. Going by data provided by Grand View Research, the global iliac stent market size was valued at $1.2 billion in 2025 and is projected to grow from $1.3 billion in 2026 to $2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Growth of the market can be attributed to growing advancements in medical technology, increasing prevalence of peripheral artery diseases and expanding awareness about minimally invasive procedures as an effective treatment option. BD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access. Currently, BDX carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI. OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today's Zacks #1 Rank stocks here. OPK has an estimated earnings growth rate of 23.3% for 2026. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%. Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. GMED has an estimated long-term earnings growth rate of 12.4%. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%. MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI's earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A medical device maker selling more and earning a third less has a cost problem rather than a demand problem. Hospitals do not stop buying syringes and catheters because the economy turns. Whatever changed here happened inside the company, which is usually the more fixable kind of trouble. BDX ranks 8th among the 10 Best Blue Chip Dividend Stocks to Buy Right Now. To see which stocks outranked it, click HERE. Becton Dickinson reports two different free cash flow figures, and only one of them answers the question most readers are asking. The levered measure is struck after debt service. The cash flow statement figure is operating cash flow less capital spending, and that is the one that tells you whether the business converts profit into money. On that basis, the conversion is healthy and comfortably exceeds reported net income, despite earnings falling 34.30%. The cash did not drop the way the profit did, which is the single strongest argument for patience here. The demand side is also intact, because revenue grew 5.40% and hospital consumables are about as predictable a revenue stream as healthcare offers, with procedure volumes moving on reimbursement rather than the economy. The dividend is covered by that cash and consumes a manageable share of earnings, which is the only test that matters for the aristocrats whose payouts have never been cut. DON'T MISS: 14 Best Pharma Dividend Stocks to Buy in 2026 Gross margin is ordinary for devices sold into hospitals. The operating line is where research, the sales force, and the amortisation of past acquisitions land. Net margin then falls to 4.19%, and that final step is the one that moved. Interest on $16.81 billion of debt sits in that gap against a cash balance under a billion. A current ratio of 0.87 means short-term obligations exceed short-term assets, which describes a balance sheet with no spare room at a company that has spent years acquiring. The forward multiple of 13.81 sits far below the trailing one of 31.58 and expects earnings per share to roughly triple, to $13.30. That is a very large recovery to price in advance, and it assumes the cost base comes down rather than the revenue going up. Device makers and drugmakers are sold on the same recovery promise, and one group has the longer record, which is the argument for the drugmakers on our 2026 dividend list. The one we rated highest there has added 13% since. Hospital budgets are also under genuine pressure, which limits how much of that recovery Becton Dickinson actually controls. Pricing a tripling of earnings in advance leaves nothing in reserve for the day it slips. The verdict is that Becton Dickinson looks reasonably valued on cash and expensive on reported earnings, and the gap between those two views is the entire investment case. What you are paying for is a cost problem being fixed at a company whose demand was never in doubt. That is a more tractable problem than most, and it is not free at this price. Buying the business before the recovery is priced in is the whole game, and that window has largely closed here. That said, it is still open across the quality companies priced below their worth. Demand was never the problem here. Revenue grew, and the cash flow statement shows a conversion comfortably above reported net income. However, net margin fell to low single digits because interest on a heavy debt load sits between the operating line and the bottom line. Short-term obligations exceed short-term assets, and the forward multiple assumes earnings per share roughly triples. Watch net margin. That is where the debt is being paid for. Becton, Dickinson and Company (NYSE:BDX) was held by 46 hedge funds with a combined stake value of about $2.18 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 48 hedge fund holders with a cumulative investment value of around $1.65 billion in the previous quarter. While we acknowledge the risk and potential of BDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDX and that has 10,000% upside potential, check out our report about this cheapest AI stock. READ NEXT: 14 Best Pharma Dividend Stocks to Buy in 2026 and 10 Best Dividend Aristocrat Stocks to Buy in 2026 This article is originally published at Insider Monkey.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Becton Dickinson (BDX), which belongs to the Zacks Medical - Dental Supplies industry. This medical device manufacturer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.78%. For the last reported quarter, Becton Dickinson came out with earnings of $3.23 per share versus the Zacks Consensus Estimate of $3.14 per share, representing a surprise of 2.87%. For the previous quarter, the company was expected to post earnings of $2.77 per share and it actually produced earnings of $2.9 per share, delivering a surprise of 4.69%. For Becton Dickinson, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Becton Dickinson currently has an Earnings ESP of +0.21%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on November 5, 2026. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the portfolio. Against that backdrop, the share price has gained 20.28% over the past 90 days despite a year-to-date share price return of a 6.25% decline, and the 1-year total shareholder return of 26.07% points to momentum that has been building rather than fading. Scan how Becton Dickinson's recent clinical and manufacturing moves compare with other potential compounders by reviewing our hand picked 27 high quality undervalued stocks in similar quality brackets. After a 90 day run that put Becton Dickinson up more than 20%, fresh trial data, a major U.S. manufacturing deal and an active recall all feed into one question: Does the current valuation still skew the risk reward toward buyers? The most followed valuation narrative puts Becton Dickinson's fair value at $195.67 against a last close of $182.75, which suggests the recent rally has not fully closed the gap that narrative followers see. The ongoing shift toward a focused medtech portfolio, in which more than 90% of revenue comes from businesses growing in the mid to high single digits and key platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration grow at double digits with higher gross margins than the corporate average, supports a richer margin mix and provides a base for revenue and earnings growth. More shareholder-friendly capital allocation following the Waters separation, including about $2.3b of share repurchases year to date in fiscal 2026, $3.1b returned to shareholders in total and $2.1b of debt retired while keeping net leverage around 2.9x, is intended to support per share earnings and return on invested capital as Becton Dickinson focuses on tuck-in deals that meet growth and margin targets. See why 27 investors see Becton Dickinson as 7% undervalued. Result: Fair Value of $195.67 (UNDERVALUED) Still, Becton Dickinson faces real pressure if China weakness persists and if recalls or FDA actions around infection prevention products expand or take longer to resolve. Find out about the key risks to this Becton Dickinson narrative. Mixed signals around Becton Dickinson can make the picture feel blurred. Move quickly, look through the full risk and reward breakdown, and weigh it against your own expectations with the help of 4 key rewards and 2 important warning signs. If Becton Dickinson has you thinking harder about where risk and reward really line up, do not stop here. Broaden your watchlist with other focused ideas that match your own return and volatility comfort zone. - Target dependable payouts by scanning companies that match your income goals using the 8 dividend fortresses. - Hunt for mispriced quality and see which opportunities line up with your checklist through the 20 high quality undiscovered gems. - Prioritize resilience by filtering for businesses with robust finances using the list of solid balance sheet and fundamentals (25 results). This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BDX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J., Oct. 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease (PAD). The findings mark an important milestone in the efforts by BD to expand clinical evidence supporting innovative solutions for chronic vascular disease and reinforce its commitment to advancing care for patients with PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello™ Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries. Iliac artery disease can reduce blood flow to the legs and feet and potentially cause symptoms such as leg pain, cramping, impaired mobility and reduced quality of life. As treatment options evolve, physicians continue to seek durable solutions that provide sustained vessel patency and favorable long-term outcomes, particularly for patients with complex iliac artery anatomy. The AGILITY iliac cohort enrolled 120 patients at 28 investigational sites in the United States, Europe, Australia and New Zealand. Through nine months of follow-up, treatment with the Revello™ Vascular Covered Stent resulted in: - Composite safety and effectiveness endpoint met with a failure rate of 2.8%, significantly below the 19% prespecified performance goal - 97.2% primary patency - 98.3% freedom from clinically driven target lesion revascularization - No device- or procedure-related deaths, target limb major amputations (at or above the ankle), or unanticipated serious adverse device effects Patients experienced meaningful gains in daily function and mobility, with mean Rutherford category improving from 3.0 at baseline to 0.3 and mean WIQ score improving by 31.7 points from baseline to 9 months. Women represented approximately 41% of enrolled patients, and slightly more than half of lesions showed moderate-to-severe calcification. "These latest data showed high primary patency and low clinically driven target lesion revascularization in a patient population that included both straightforward and complex iliac lesions," said Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic and global lead principal investigator for AGILITY. "Results showed the treated arteries remained open in a high percentage of patients, and at nine months, patients also showed changes in disease severity and walking ability." "These results reflect the continued commitment of BD to advance evidence-based innovation in peripheral vascular care," said Rob Righi, vice president and general manager of the Vascular Platform, Peripheral Intervention at BD. "As follow-up continues, the AGILITY study will help further characterize the Revello™ Vascular Covered Stent's performance across patients with peripheral artery disease." Clinical follow-up in the iliac cohort is ongoing through 36 months. BD also completed enrollment in the study's superficial femoral and proximal popliteal artery cohort this past August, marking another milestone in the AGILITY study. The Revello™ Vascular Covered Stent is CE marked. In the United States, the Revello™ Vascular Covered Stent is an investigational device limited by U.S. law to investigational use only. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. Contacts: | Media | Investors Matt Marcus VP, Public Relations [email protected] | Shawn BevecSVP, Investor [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-strengthens-leadership-in-peripheral-vascular-innovation-with-positive-agility-trial-results-302900377.html